SCHEMBL10064679

SCHEMBL10064679

Cc1ccc(S(=O)(=O)N2CCCCCC2)cc1C(=O)Nc1cccc(O)c1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 6/20 0.77
▸ ALDH1A1 P00352 5/20 0.77
▸ TSHR P16473 2/20 0.77
▸ HTT P42858 2/20 0.77
▸ POLB P06746 4/20 0.71
▸ TDP1 Q9NUW8 4/20 0.71
▸ MAPT P10636 3/20 0.71
▸ RECQL P46063 2/20 0.71
▸ CTDSP1 Q9GZU7 1/20 0.71
▸ MEN1 O00255 4/20 0.69
▸ KMT2A Q03164 4/20 0.69
▸ TP53 P04637 2/20 0.67
▸ RAB9A P51151 1/20 0.67
▸ SMN1; SMN2 Q16637 1/20 0.64
▸ L3MBTL1 Q9Y468 3/20 0.63
▸ APEX1 P27695 1/20 0.63
▸ HSD17B10 Q99714 2/20 0.63
▸ ALPL P05186 1/20 0.63
▸ NR4A1 P22736 1/20 0.63
▸ ESR2 Q92731 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1093544 0.88 ALDH1A1 (0.98) LMNAALDH1A1TSHRHTTMAPT
SCHEMBL31609945 0.87 ALDH1A1 (0.71) LMNAALDH1A1TSHRHTTPOLB
SCHEMBL1094755 0.80 TP53 (1.00) LMNAALDH1A1TSHRHTTMAPT
SCHEMBL15612958 0.80 ALDH1A1 (0.77) LMNAALDH1A1TSHRHTTPOLB
SCHEMBL17479356 0.78 LMNA (0.70) LMNAALDH1A1TSHRHTTMAPT
SCHEMBL15076653 0.78 TP53 (1.00) LMNAALDH1A1MAPTTP53SMN1; SMN2
SCHEMBL15076661 0.77 TP53 (0.86) LMNAALDH1A1TSHRMAPTTP53
SCHEMBL17479327 0.77 MAPT (0.63) LMNAALDH1A1TSHRHTTPOLB
SCHEMBL4717672 0.76 TSHR (0.72) ALDH1A1TSHRPOLBTDP1MAPT
SCHEMBL22062413 0.76 MEN1 (0.78) LMNAALDH1A1TDP1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153803-B2 Compositions and methods for modulating sirtuin activity THE GENERAL HOSPITAL CORPORATION (US) 2012-04-10 — — US disclosed
US-20090259044-A1 COMPOSITIONS AND METHODS FOR MODULATING SIRTUIN ACTIVITY THE GENERAL HOSPITAL CORPORATION (US) 2009-10-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090259044-A1 COMPOSITIONS AND METHODS FOR MODULATING SIRTUIN ACTIVITY SIRT2, SIRT1, SIRT3 LMNA 2233/4885ALDH1A1 1544/4885TSHR 4458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback